Alza Brings Ditropan XL To Abbott As Near-Term Project In $7.3 Bil. Merger
Abbott would expand its urologic products franchise with the urinary incontinence treatment Ditropan XL as one of the immediate effects of its proposed acquisition of Alza.
Abbott would expand its urologic products franchise with the urinary incontinence treatment Ditropan XL as one of the immediate effects of its proposed acquisition of Alza.